A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects

Clinical trial NCT03156101 · UNKNOWN

Trial details

NCT number: NCT03156101
Sponsor: Shenzhen BinDeBio Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed B-cell Acute Lymphoblastic Leukemia Refractory B-cell Acute Lymphoblastic Leukemia Relapsed／Refractory B-cell Lymphoma

Start date: 2017-03-02
Primary completion: 2021-05-30
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.